If this message does not display properly, please click here to launch your browser.
|
Based on our Methicillin-resistant Staphylococcus aureus (MRSA) and Hospital-Acquired Infections Pharmacor advisory services, Decision Resources is offering an exclusive analyst call entitled The Rising Threat of Gram-Negative Infections and Multi-Drug Resistant Gram-Negative Strains - News from ICAAC. Because this presentation will feature major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services. Please contact us learn how you can purchase one or both of these Pharmacor advisory services and attend the analyst call. Hospital-acquired gram-negative infections represent an area of high unmet need and untapped drug development opportunity in the antibacterial market. Consistent with the expansion of antibacterial drug development focus to include gram-negative infections in addition to MRSA, the predominant theme at this year’s 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) event was the heightened awareness and rising threat of gram-negative infections, especially the increase in multi-drug resistant (MDR) gram-negative strains. Data presented at the conference strongly echoed clinicians’ concern over the immediate need for novel agents against MDR gram-negative pathogens. This 15-minute analyst call, presented by Decision Resources Analyst Charu Vepari, Ph.D., will answer the following questions:
Dr. Vepari will conduct a live Q & A session after the presentation. Registration The Rising Threat of Gram-Negative Infections and Multi-Drug Resistant Gram-Negative Strains - News from ICAAC October 7, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase one or both of these Pharmacor advisory services and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Charu Vepari, Ph.D., is an analyst in the infectious diseases group at Decision Resources. Prior to joining the company, she served in several teaching roles, including as an instructor at Tufts University and as an adjunct professor of bioengineering at Olin College of Engineering, where she taught an undergraduate course on topics in bioengineering. Dr. Vepari also worked at Wyeth as a process development associate. Part of her duties there were to develop and validate purification processes of recombinant protein biologics and to support investigational new drug (IND) and biologics license application (BLA) filings. She earned a B.S. in biotechnology from Worcester Polytechnic Institute and a Ph.D. in chemical and bioengineering from Tufts University, where she studied special surface functionalization to control cell responses.